One-Stop TCR-T Therapy Development Services at Creative Biolabs Ready to Advance Tumor Research

New York City, New York May 22, 2022 (Issuewire.com) - As tebentafusp, the bispecific molecule to engage tumor antigens via T cell receptor (TCR) targeting, won approval from the US Food and Drug Administration (FDA) in January 2022, TCR-based therapies gain more attention from global scientists. Among all kinds, TCR-T therapy is recognized as powerful immunotherapy to treat tumors, but its complexity makes it challenging in design, preclinical optimization, and clinical trials.

Empowered by leading CAR/TCR technology and platform, as well as years of experience in biomedical science, Creative Biolabs offers a broad range of TCR-T therapy early development services, covering biomarker identification and selection, design, construction, generation, optimization, gene packaging and delivery, analysis, assays, and HLA typing.

• TCR Design & Construction

Creative Biolabs has been devoted to the design of TCR-T therapy for many years. The scientist team is skillful in altering the specificity of TCR to genetically modify T cells to enhance their tumor-killing activity. In addition, based on the general method of TCR construction, Creative Biolabs optimizes the strategies by combining the conventional steps into a single process, thus expediting TCR vector production. This one-step approach greatly streamlines the TCR vector production process.

• TCR Generation & Optimization

Scientists at Creative Biolabs can offer several innovative approaches to generate TCRs that are specific for the antigens that are expressed by a wider variety of tumor cell types to meet special needs. Particularly, the team highlights a special pipeline of antigen-specific TCR-T cell generation in terms of the method of direct targeting of human tumors using autologous tumor-infiltrating lymphocytes (TILs). TCRs generated from phage display and self-established TCR transgenic models are also available.

Creative Biolabs also offers 3 classic strategies to alter the specificity of TCR, including TCR C Domain Murinization, Incorporation of Additional Cysteine Residue, and Increasing Avidity. Some vital methods/steps, such as untargeted mutagenesis, oligonucleotide-directed mutagenesis, and phage display antibody library screening, will help clients obtain higher TCR affinity mature level for many efficient results in further research

• HLA Typing

Creative Biolabs has developed a dedicated NGS-based HLA typing service with the promise of precise and high-resolution results for a wide range of HLA types-A, B, C, G, DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, DPB1, etc. The workflow includes sample preparation, HLA CR, library construction, NGS sequencing, and data analysis.

More information can be reached at https://www.creative-biolabs.com/car-t/.

About Creative Biolabs

With years of exploration in biotechnology, Creative Biolabs has gathered talented scientists working closely with worldwide partners to develop and produce the medicines of tomorrow. Specifically, Creative Biolabs specializes in one-stop custom services for CAR-T therapy development, dendritic cell therapy development, TCR modified T cell development, CAR-macrophage therapy development, cancer vaccine development, etc.

Media Contact

Candy Swift

[email protected]

https://www.creative-biolabs.com/car-t/